Effect of EGb 761 on the ratio of the isoforms of the protein precursor of beta amyloid platelets on patients with mild to moderate Alzheimer's disease. A phase II, randomised, double-blind trial, on parallel groups versus placebo
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs EGb 761 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 26 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Aug 2007 New trial record.